Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 161
Filter
1.
J Med Chem ; 64(12): 8287-8302, 2021 06 24.
Article in English | MEDLINE | ID: mdl-34081480

ABSTRACT

Recycling of all-trans-retinal to 11-cis-retinal through the visual cycle is a fundamental metabolic pathway in the eye. A potent retinoid isomerase (RPE65) inhibitor, (R)-emixustat, has been developed and tested in several clinical trials; however, it has not received regulatory approval for use in any specific retinopathy. Rapid clearance of this drug presents challenges to maintaining concentrations in eyes within a therapeutic window. To address this pharmacokinetic inadequacy, we rationally designed and synthesized a series of emixustat derivatives with strategically placed fluorine and deuterium atoms to slow down the key metabolic transformations known for emixustat. Crystal structures and quantum chemical analysis of RPE65 in complex with the most potent emixustat derivatives revealed the structural and electronic bases for how fluoro substituents can be favorably accommodated within the active site pocket of RPE65. We found a close (∼3.0 Å) F-π interaction that is predicted to contribute ∼2.4 kcal/mol to the overall binding energy.


Subject(s)
Eye/metabolism , Phenyl Ethers/pharmacokinetics , Propanolamines/pharmacokinetics , Amine Oxidase (Copper-Containing)/metabolism , Animals , Cattle , Cell Adhesion Molecules/metabolism , Crystallography, X-Ray , Deuterium/chemistry , Drug Design , Fluorine/chemistry , Halogenation , Mice , Molecular Structure , Phenyl Ethers/chemical synthesis , Phenyl Ethers/metabolism , Propanolamines/chemical synthesis , Propanolamines/metabolism , Protein Binding , Structure-Activity Relationship , cis-trans-Isomerases/metabolism
2.
Pharmacol Res Perspect ; 9(3): e00792, 2021 05.
Article in English | MEDLINE | ID: mdl-34018344

ABSTRACT

The management of Parkinson's disease (PD) is frequently compromised by complications induced by dopaminergic treatment such as involuntary movements (dyskinesias) and psychosis. Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist developed for the management of complications of therapy in PD. This study evaluated the safety, tolerability, and pharmacokinetics of escalating single and multiple doses of mesdopetam. We conducted a prospective, single-center, randomized, double-blind, placebo-controlled phase I, and first-in-human (FIH) study with mesdopetam administered to healthy male subjects. Overall, mesdopetam was well-tolerated up to a 120 mg single dose and up to 80 mg upon multiple dosing. Adverse events (AEs) were mainly related to the nervous system and were dose-dependent. No serious adverse events occurred and no AEs led to withdrawal. The results of the single-ascending-dose and multiple-ascending-dose parts indicated dose- and time-independent pharmacokinetics with rapid absorption and maximum plasma levels that were generally reached within 2 h after dosing. No accumulation was observed upon multiple dosing. It is concluded that mesdopetam was safe and well-tolerated in healthy male volunteers. Pharmacokinetic analysis indicated rapid absorption and dose-linear pharmacokinetics of mesdopetam, with a plasma half-life of around 7 h, upon single and repeated dosing. The pharmacokinetics of mesdopetam supports twice-daily use in patients.


Subject(s)
Dopamine Antagonists/administration & dosage , Phenyl Ethers/administration & dosage , Propylamines/administration & dosage , Receptors, Dopamine D3/antagonists & inhibitors , Administration, Oral , Adolescent , Adult , Biological Availability , Dopamine Antagonists/adverse effects , Dopamine Antagonists/pharmacokinetics , Dose-Response Relationship, Drug , Double-Blind Method , Fasting/metabolism , Food-Drug Interactions , Half-Life , Healthy Volunteers , Humans , Male , Middle Aged , Phenyl Ethers/adverse effects , Phenyl Ethers/pharmacokinetics , Propylamines/adverse effects , Propylamines/pharmacokinetics , Young Adult
3.
Eur J Drug Metab Pharmacokinet ; 46(3): 395-404, 2021 May.
Article in English | MEDLINE | ID: mdl-33782834

ABSTRACT

BACKGROUND: Vixotrigine is a voltage and use dependent sodium channel blocker currently under development for treatment of various neuropathic pain indications. OBJECTIVE: The objective of this work was to develop a population pharmacokinetic model and assess effects of various covariates on pharmacokinetic parameters of vixotrigine. METHOD: Plasma concentration-time data from 12 Phase 1 or 2 studies were included in the analyses. The data were obtained following administration of single or multiple doses of vixotrigine in healthy volunteers and patients. One- and two-compartment pharmacokinetic models were evaluated as base structural pharmacokinetic models. The inclusion of selected covariates was assessed using a stepwise backward elimination approach (α = 0.001) once the base/full model was developed. The predictive ability of the model was evaluated using a visual predictive check (VPC). The final model was used to evaluate effect of covariates on exposure of vixotrigine. RESULTS: A total of 10,263 pharmacokinetic samples collected from 465 subjects were included in the analyses. The pharmacokinetics of vixotrigine was adequately described by a two-compartment model with two transit absorption compartments and first-order elimination. Predictability of the model was also established by VPC. The final model included covariates of age, weight and carbamazepine co-administration on clearance, weight on central volume of distribution, food on absorption rate constant and formulation and Japanese race on bioavailability. None of the covariates identified had a clinically relevant effect, as impact on area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) was within ± 25%. CONCLUSION: The model characterizes the pharmacokinetics of vixotrigine well, and the exposure of vixotrigine was comparable between healthy subjects and patients. None of the covariates evaluated have a clinically relevant impact on the pharmacokinetics of vixotrigine.


Subject(s)
Models, Biological , Phenyl Ethers/pharmacokinetics , Proline/analogs & derivatives , Voltage-Gated Sodium Channel Blockers/pharmacokinetics , Adolescent , Adult , Aged , Aged, 80 and over , Area Under Curve , Asian People , Biological Availability , Erythromelalgia/drug therapy , Female , Food-Drug Interactions , Humans , Male , Middle Aged , Phenyl Ethers/administration & dosage , Proline/administration & dosage , Proline/pharmacokinetics , Radiculopathy/drug therapy , Tissue Distribution , Trigeminal Neuralgia/drug therapy , Voltage-Gated Sodium Channel Blockers/administration & dosage , Young Adult
4.
Clin Pharmacokinet ; 60(1): 121-131, 2021 01.
Article in English | MEDLINE | ID: mdl-32856281

ABSTRACT

BACKGROUND AND OBJECTIVE: Ampreloxetine is a novel norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension. The objectives of this analysis were to define the pharmacokinetics of once-daily oral ampreloxetine and provide dose recommendations for clinical development. METHODS: We fitted a population pharmacokinetic model to ampreloxetine plasma concentrations from single- and multiple-ascending dose trials in healthy subjects and two phase II studies in adult subjects with attention-deficit/hyperactive disorder or fibromyalgia at doses of 2-50 mg. RESULTS: Ampreloxetine pharmacokinetics was best described by a two-compartment model with first-order absorption and elimination. The terminal half-life was 30-40 h, resulting in sustained drug concentrations for the entire 24-h dosing interval at steady state. Covariates of age, weight, or renal impairment did not impact ampreloxetine exposure. Cytochrome P450 2D6 phenotype had no influence on ampreloxetine exposure. Sex and smoking status were identified as statistically significant covariates, suggesting a role for cytochrome P450 1A2 in the elimination of ampreloxetine. Despite statistical significance, differences in ampreloxetine exposure in male vs female subjects and smokers vs non-smokers were not clinically meaningful at the recommended dose. At the 10-mg dose, > 75% norepinephrine transporter inhibition and < 50% serotonin transporter inhibition are anticipated for adult subjects. CONCLUSIONS: The population pharmacokinetic model effectively described the plasma concentration-time profile of ampreloxetine after single and multiple doses. Population pharmacokinetic/pharmacodynamic analysis justified using a fixed dosing regimen with no dose adjustments across a broad population and can be used to inform dosing strategies in future clinical studies. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier numbers NCT01693692 (fibromyalgia); NCT01458340 (attention-deficit/hyperactive disorder).


Subject(s)
Attention Deficit Disorder with Hyperactivity , Fibromyalgia , Phenyl Ethers , Piperidines , Adult , Attention Deficit Disorder with Hyperactivity/drug therapy , Attention Deficit Disorder with Hyperactivity/metabolism , Case-Control Studies , Female , Fibromyalgia/drug therapy , Fibromyalgia/metabolism , Humans , Male , Norepinephrine , Pain/drug therapy , Pain/metabolism , Phenyl Ethers/administration & dosage , Phenyl Ethers/pharmacokinetics , Piperidines/administration & dosage , Piperidines/pharmacokinetics
5.
Clin Transl Sci ; 14(4): 1272-1279, 2021 07.
Article in English | MEDLINE | ID: mdl-33278330

ABSTRACT

Neuropathic pain affects ~ 6.9-10% of the general population and leads to loss of function, anxiety, depression, sleep disturbance, and impaired cognition. Here, we report the safety, tolerability, and pharmacokinetics of a voltage-dependent and use-dependent sodium channel blocker, vixotrigine, currently under investigation for the treatment of neuropathic pain conditions. The randomized, placebo-controlled, phase I clinical trials were split into single ascending dose (SAD) and multiple ascending dose (MAD) studies. Healthy volunteers received oral vixotrigine as either single doses followed by a ≥ 7-day washout period for up to 5 dosing sessions (SAD, n = 30), or repeat doses (once or twice daily) for 14 and 28 days (MAD, n = 51). Adverse events (AEs), maximum observed vixotrigine plasma concentration (Cmax ), area under the concentration-time curve from predose to 24 hours postdose (AUC0-24 ), time to Cmax (Tmax ), and terminal half-life (t1/2), among others, were assessed. Drug-related AEs were reported in 47% and 53% of volunteers in the SAD and MAD studies, respectively, with dizziness as the most commonly reported drug-related AE. SAD results showed that Cmax and AUC increased with dose, Tmax was 1-2 hours, and t1/2 was ~ 11 hours. A twofold increase in accumulation was observed when vixotrigine was taken twice vs. once daily (MAD). Steady-state was achieved from day 5 onward. These data indicate that oral vixotrigine is well-tolerated when administered as single doses up to 825 mg and multiple doses up to 450 mg twice daily.


Subject(s)
Dizziness/epidemiology , Phenyl Ethers/adverse effects , Proline/analogs & derivatives , Sodium Channel Blockers/adverse effects , Administration, Oral , Adolescent , Adult , Aged , Area Under Curve , Dizziness/chemically induced , Dose-Response Relationship, Drug , Double-Blind Method , Female , Half-Life , Healthy Volunteers , Humans , Male , Middle Aged , Neuralgia/drug therapy , Phenyl Ethers/administration & dosage , Phenyl Ethers/pharmacokinetics , Proline/administration & dosage , Proline/adverse effects , Proline/pharmacokinetics , Sodium Channel Blockers/administration & dosage , Sodium Channel Blockers/pharmacokinetics , Young Adult
6.
Arch Pharm Res ; 43(12): 1356-1363, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33245517

ABSTRACT

The aim of this study was to investigate the effects of paroxetine, a potent inhibitor of CYP2D6, on the pharmacokinetics of atomoxetine and its two metabolites, 4-hydroxyatomoxetine and N-desmethylatomoxetine, in different CYP2D6 genotypes. Twenty-six healthy subjects were recruited and divided into CYP2D6*wt/*wt (*wt=*1 or *2, n = 10), CYP2D6*wt/*10 (n = 9), and CYP2D6*10/*10 groups (n = 7). In atomoxetine phase, all subjects received a single oral dose of atomoxetine (20 mg). In paroxetine phase, after administration of a single oral dose of paroxetine (20 mg) for six consecutive days, all subjects received a single oral dose of atomoxetine with paroxetine. Plasma concentrations of atomoxetine and its metabolites were determined up to 24 h after dosing. During atomoxetine phase, there were significant differences in Cmax and AUC0-24 of atomoxetine and N-desmethylatomoxetine among three genotype groups, whereas significant differences were not found in relation to CYP2D6*10 allele after administration of paroxetine. AUC ratios of 4-hydroxyatomoxetine and N-desmethylatomoxetine to atomoxetine were significantly different among three genotype groups during atomoxetine phase (all, P < 0.001), but after paroxetine treatment significant differences were not found. After paroxetine treatment, AUC0-24 of atomoxetine was increased by 2.3-, 1.7-, and 1.3-fold, in CYP2D6*wt/*wt, CYP2D6*wt/*10, and CYP2D6*10/*10 groups in comparison to atomoxetine phase, respectively. AUC ratio of 4-hydroxyatomoxetine to atomoxetine in each group was significantly decreased, whereas AUC ratio of N-desmethylatomoxetine to atomoxetine significantly increased after administration of paroxetine. In conclusion, paroxetine coadministration significantly affected pharmacokinetic parameters of atomoxetine and its two metabolites, 4-hydroxyatomoxetine and N-desmethylatomoxetine. When atomoxetine was administered alone, Cmax, AUC0-24 and CL/F of atomoxetine were significantly different among the three CYP2D6 genotype groups. However, after paroxetine coadministration, no significant differences in these pharmacokinetic parameters were observed among the CYP2D6 genotype groups.


Subject(s)
Atomoxetine Hydrochloride/pharmacokinetics , Cytochrome P-450 CYP2D6 Inhibitors/pharmacology , Cytochrome P-450 CYP2D6/metabolism , Paroxetine/pharmacology , Pharmacogenomic Variants , Phenols/pharmacokinetics , Phenyl Ethers/pharmacokinetics , Propylamines/pharmacokinetics , Administration, Oral , Adult , Atomoxetine Hydrochloride/administration & dosage , Biotransformation , Cytochrome P-450 CYP2D6/genetics , Drug Interactions , Female , Genotype , Humans , Male , Models, Biological , Pharmacogenetics , Young Adult
7.
Clin Pharmacol Drug Dev ; 9(1): 62-73, 2020 01.
Article in English | MEDLINE | ID: mdl-31650711

ABSTRACT

Vixotrigine is a voltage- and use-dependent Nav1.7 channel blocker under investigation for the treatment of peripheral neuropathic pain conditions, including trigeminal neuralgia. Vixotrigine is metabolized primarily via uridine diphosphate-glucuronosyltransferases (UGTs). Carbamazepine, a UGT and cytochrome P450 3A4 inducer, is a first-line treatment for trigeminal neuralgia. We conducted a double-blind, randomized, placebo-controlled, parallel-group, single-center phase 1 study to investigate the impact of coadministering vixotrigine and carbamazepine on their respective pharmacokinetics (PK) in healthy volunteers, the safety and tolerability of combined treatment, and PK recovery of vixotrigine following carbamazepine discontinuation. Randomly assigned treatments were carbamazepine (100 mg twice a day, days 1-3 and 200 mg twice a day, days 4-21) or placebo on days 1 to 21. All volunteers received vixotrigine 150 mg 3 times a day on days 16 to 28. At prespecified times, whole-blood samples were collected for PK assessment. Statistical analyses were performed on the log-transformed PK parameters area under the concentration-time curve within a dosing interval (AUC0-tau ) and maximum observed concentration (Cmax ) for vixotrigine, carbamazepine, and metabolites. Vixotrigine AUC0-tau and Cmax were reduced by 31.6% and 26.3%, respectively, when coadministered with carbamazepine compared with placebo. Seven days after carbamazepine discontinuation, vixotrigine AUC0-tau and Cmax remained 24.5% and 21.4% lower compared with placebo. Carbamazepine AUC0-tau and Cmax were <10% lower when coadministered with vixotrigine compared on days 15 and 21. Vixotrigine/carbamazepine coadministration was well tolerated. These results suggest that vixotrigine does not have an effect on carbamazepine PK, and although carbamazepine has an effect on the exposure of vixotrigine, the effect is not considered clinically relevant.


Subject(s)
Analgesics, Non-Narcotic/pharmacology , Carbamazepine/pharmacology , Phenyl Ethers/pharmacokinetics , Proline/analogs & derivatives , Voltage-Gated Sodium Channel Blockers/pharmacokinetics , Adult , Analgesics, Non-Narcotic/adverse effects , Analgesics, Non-Narcotic/pharmacokinetics , Carbamazepine/adverse effects , Carbamazepine/pharmacokinetics , Double-Blind Method , Drug Interactions , Drug Therapy, Combination , Female , Healthy Volunteers , Humans , Male , NAV1.7 Voltage-Gated Sodium Channel , Phenyl Ethers/adverse effects , Phenyl Ethers/blood , Phenyl Ethers/pharmacology , Proline/adverse effects , Proline/blood , Proline/pharmacokinetics , Proline/pharmacology , Voltage-Gated Sodium Channel Blockers/adverse effects , Voltage-Gated Sodium Channel Blockers/blood , Young Adult
8.
J Clin Pharmacol ; 59(1): 90-97, 2019 01.
Article in English | MEDLINE | ID: mdl-30144099

ABSTRACT

Vixotrigine is a state- and use-dependent Nav1.7 channel blocker being investigated for the treatment of neuropathic pain conditions. This randomized, double-blind, placebo-controlled crossover trial was designed to evaluate changes in blood pressure with the administration of vixotrigine using ambulatory blood pressure monitoring (ABPM). Eligible participants were healthy adults 18 to 65 years of age without evidence of baseline systolic blood pressure (SBP) persistently > 140 mm Hg or diastolic blood pressure (DBP) persistently > 90 mm Hg. Vixotrigine (400 mg [men], 300 mg [women]) or placebo was administered orally twice daily for 36 days. Following a 7-day washout period, participants crossed over to the other treatment. Each dosing period was preceded by 1 inpatient visit and 1 outpatient baseline visit. Two 14-hour inpatient ABPM sessions occurred on days 14 and 35, with a return to the clinic the morning of days 15 and 36 for initiation of outpatient ABPM, which assessed blood pressure and heart rate every 15 minutes. Adverse events were collected throughout the study. The primary end point was the change from baseline in 24-hour mean SBP and DBP on day 36. Sixty participants were enrolled; 10 withdrew from the study owing to adverse events, investigator discretion, or withdrawal of consent. From baseline to day 36, mean changes in average SBP and DBP (vixotrigine treated) were -0.33 and 0.20 mm Hg, respectively. Adverse event rates were comparable for vixotrigine and placebo; the most common adverse events were headache, dizziness, and nausea. Vixotrigine administration is not associated with a clinically important increase in blood pressure.


Subject(s)
Blood Pressure/drug effects , Phenyl Ethers/pharmacology , Proline/analogs & derivatives , Sodium Channel Blockers/pharmacology , Adult , Blood Pressure Monitoring, Ambulatory , Cross-Over Studies , Double-Blind Method , Female , Humans , Male , Middle Aged , Models, Biological , NAV1.7 Voltage-Gated Sodium Channel/physiology , Phenyl Ethers/adverse effects , Phenyl Ethers/pharmacokinetics , Proline/adverse effects , Proline/pharmacokinetics , Proline/pharmacology , Sodium Channel Blockers/adverse effects , Sodium Channel Blockers/pharmacokinetics , Young Adult
9.
Biochemistry ; 57(30): 4518-4525, 2018 07 31.
Article in English | MEDLINE | ID: mdl-29975048

ABSTRACT

Inhibitors of phosphodiesterases (PDEs) have been widely studied as therapeutics for the treatment of human diseases, but improvement of inhibitor selectivity is still desirable for the enhancement of inhibitor potency. Here, we report identification of a water-containing subpocket as a PDE4-specific pocket for inhibitor binding. We designed against the pocket and synthesized two enantiomers of PDE4 inhibitor Zl-n-91. The ( S)-Zl-n-91 enantiomer showed IC50 values of 12 and 20 nM for the catalytic domains of PDE4D2 and PDE4B2B, respectively, selectivity several thousand-fold greater than those of other PDE families, and potent neuroprotection activities. Crystal structures of the PDE4D2 catalytic domain in complex with each Zl-n-91 enantiomer revealed that ( S)-Zl-n-91 but not ( R)-Zl-n-91 formed a hydrogen bond with the bound water in the pocket, thus explaining its higher affinity. The structural superposition between the PDE families revealed that this water-containing subpocket is unique to PDE4 and thus valuable for the design of PDE4 selective inhibitors.


Subject(s)
Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism , Drug Design , Furans/chemistry , Furans/pharmacology , Phenyl Ethers/chemistry , Phenyl Ethers/pharmacology , Phosphodiesterase 4 Inhibitors/chemistry , Phosphodiesterase 4 Inhibitors/pharmacology , Animals , Binding Sites/drug effects , Catalytic Domain/drug effects , Cyclic Nucleotide Phosphodiesterases, Type 4/chemistry , Furans/pharmacokinetics , Humans , Hydrogen Bonding/drug effects , Male , Memory/drug effects , Mice, Inbred ICR , Molecular Docking Simulation , Phenyl Ethers/pharmacokinetics , Phosphodiesterase 4 Inhibitors/pharmacokinetics , Rolipram/analogs & derivatives , Rolipram/pharmacokinetics , Rolipram/pharmacology , Stereoisomerism , Water/chemistry
10.
Diabetes ; 67(2): 182-192, 2018 02.
Article in English | MEDLINE | ID: mdl-29208633

ABSTRACT

GPR44 expression has recently been described as highly ß-cell selective in the human pancreas and constitutes a tentative surrogate imaging biomarker in diabetes. A radiolabeled small-molecule GPR44 antagonist, [11C]AZ12204657, was evaluated for visualization of ß-cells in pigs and nonhuman primates by positron emission tomography as well as in immunodeficient mice transplanted with human islets under the kidney capsule. In vitro autoradiography of human and animal pancreatic sections from subjects without and with diabetes, in combination with insulin staining, was performed to assess ß-cell selectivity of the radiotracer. Proof of principle of in vivo targeting of human islets by [11C]AZ12204657 was shown in the immunodeficient mouse transplantation model. Furthermore, [11C]AZ12204657 bound by a GPR44-mediated mechanism in pancreatic sections from humans and pigs without diabetes, but not those with diabetes. In vivo [11C]AZ12204657 bound specifically to GPR44 in pancreas and spleen and could be competed away dose-dependently in nondiabetic pigs and nonhuman primates. [11C]AZ12204657 is a first-in-class surrogate imaging biomarker for pancreatic ß-cells by targeting the protein GPR44.


Subject(s)
Diabetes Mellitus, Type 1/diagnostic imaging , Diabetes Mellitus, Type 2/diagnostic imaging , Insulin-Secreting Cells/pathology , Islets of Langerhans/diagnostic imaging , Phenyl Ethers/pharmacokinetics , Receptors, Immunologic/metabolism , Receptors, Prostaglandin/metabolism , Animals , Autoradiography , Biomarkers/metabolism , Biopsy , Carbon Radioisotopes , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 1/pathology , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/pathology , Humans , Insulin-Secreting Cells/metabolism , Intestinal Elimination , Islets of Langerhans/metabolism , Islets of Langerhans/pathology , Islets of Langerhans Transplantation/diagnostic imaging , Islets of Langerhans Transplantation/pathology , Ligands , Macaca fascicularis , Magnetic Resonance Imaging , Mice, Nude , Phenyl Ethers/administration & dosage , Positron Emission Tomography Computed Tomography , Proof of Concept Study , Receptors, Immunologic/antagonists & inhibitors , Receptors, Prostaglandin/antagonists & inhibitors , Sus scrofa , Tissue Distribution , Transplantation, Heterologous , Transplantation, Heterotopic
11.
Mol Neurobiol ; 55(5): 3931-3945, 2018 May.
Article in English | MEDLINE | ID: mdl-28550529

ABSTRACT

Studies suggest that the blockade of 5-HT1A, 5-HT7, and 5-HT3 receptor may increase the speed of antidepressant response. 1-[(2,6-Dimethylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-14) and 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride (HBK-15), dual 5-HT1A and 5-HT7 antagonists, showed significant antidepressant- and anxiolytic-like properties in our previous tests in rodents. In this study, we aimed to investigate their antidepressant potential using mouse model of corticosterone-induced depression. We chose sucrose preference test, forced swim test, and elevated plus maze to determine anhedonic-, antidepressant-, and anxiolytic-like activities. We also evaluated the influence of the active compound on brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus. Moreover, for both compounds, we performed biofunctional (5-HT3 receptor) and pharmacokinetic studies. We found that HBK-14 and HBK-15 were potent 5-HT3 receptor antagonists. HBK-14 (2.5 mg/kg) and HBK-15 (1.25 mg/kg) after intravenous (i.v.) and intraperitoneal (i.p.) administration permeated the blood-brain barrier with brain/plasma ratio lower than 1. The bioavailability of studied compounds after i.p. administration was 15% for HBK-14 and 54% for HBK-15. Chronic administration of HBK-15 (1.25 mg/kg) and fluoxetine (10 mg/kg) protected corticosterone-treated mice from anhedonic-, depressive-, and anxiety-like behaviors, as well as decreases in BDNF and NGF levels in the hippocampus. HBK-14 (2.5 mg/kg) counteracted anxiety-like behaviors in corticosterone-treated mice. Single administration of HBK-15 (1.25 mg/kg) and ketamine (1 mg/kg) reversed depression-like behavior and regulated decreased BDNF level in the hippocampus in corticosterone-treated mice. Our results suggest that simultaneous blockade of serotonergic 5-HT1A, 5-HT7, and 5-HT3 receptors might accelerate antidepressant response.


Subject(s)
Behavior, Animal , Depression/drug therapy , Phenyl Ethers/administration & dosage , Phenyl Ethers/therapeutic use , Piperazines/administration & dosage , Piperazines/therapeutic use , Receptors, Serotonin/metabolism , Serotonin Antagonists/therapeutic use , Animals , Corticosterone , Depression/blood , Disease Models, Animal , Guinea Pigs , Ileum/drug effects , Ileum/physiology , Male , Mice , Muscle Contraction/drug effects , Phenyl Ethers/blood , Phenyl Ethers/chemistry , Phenyl Ethers/pharmacokinetics , Phenyl Ethers/pharmacology , Piperazines/blood , Piperazines/chemistry , Piperazines/pharmacokinetics , Piperazines/pharmacology , Serotonin/pharmacology , Serotonin Antagonists/blood , Serotonin Antagonists/chemistry , Serotonin Antagonists/pharmacokinetics
12.
Xenobiotica ; 48(6): 592-604, 2018 Jun.
Article in English | MEDLINE | ID: mdl-28678597

ABSTRACT

1. Emixustat is a small molecule that potently inhibits retinal pigment epithelium 65 isomerohydrolase. Emixustat is in clinical development for the treatment of various retinopathies (i.e. Stargardt disease and diabetic retinopathy). 2. A human absorption, distribution, metabolism, and excretion (ADME) study was conducted with a single dose of [14C]-emixustat in healthy male subjects. Total 14C content in plasma, urine, and faeces was determined using accelerator mass spectrometry (AMS), and metabolic profiles in pooled plasma and urine were investigated by both HPLC-AMS and 2D LC-MS/MS. 3. After a single, oral 40-mg dose of [14C]-emixustat, recovery of total 14C was nearly complete within 24 h. Urine was the major route of 14C elimination; accounting for > 90% of the administered dose. 4. Biotransformation of emixustat occurred primarily at two structural moieties; oxidation of the cyclohexyl moiety and oxidative deamination of the 3R-hydroxypropylamine, both independently and in combination to produce secondary metabolites. Metabolite profiling in pooled plasma samples identified 3 major metabolites: ACU-5124, ACU-5116 and ACU-5149, accounting for 29.0%, 11.5%, and 10.6% of total 14C, respectively. Emixustat was metabolized in human hepatocytes with unchanged emixustat accounting for 33.7% of sample radioactivity and predominantly cyclohexanol metabolites observed.


Subject(s)
Hepatocytes/metabolism , Phenyl Ethers , Propanolamines , Adult , Biotransformation , Cells, Cultured , Hepatocytes/cytology , Humans , Male , Middle Aged , Phenyl Ethers/administration & dosage , Phenyl Ethers/pharmacokinetics , Propanolamines/administration & dosage , Propanolamines/pharmacokinetics
13.
PLoS One ; 12(7): e0180319, 2017.
Article in English | MEDLINE | ID: mdl-28746336

ABSTRACT

The beta-1 adrenergic receptor (ADRB1) is a promising therapeutic target intrinsically involved in the cognitive deficits and pathological features associated with Alzheimer's disease (AD). Evidence indicates that ADRB1 plays an important role in regulating neuroinflammatory processes, and activation of ADRB1 may produce neuroprotective effects in neuroinflammatory diseases. Novel small molecule modulators of ADRB1, engineered to be highly brain permeable and functionally selective for the G protein with partial agonistic activity, could have tremendous value both as pharmacological tools and potential lead molecules for further preclinical development. The present study describes our ongoing efforts toward the discovery of functionally selective partial agonists of ADRB1 that have potential therapeutic value for AD and neuroinflammatory disorders, which has led to the identification of the molecule STD-101-D1. As a functionally selective agonist of ADRB1, STD-101-D1 produces partial agonistic activity on G protein signaling with an EC50 value in the low nanomolar range, but engages very little beta-arrestin recruitment compared to the unbiased agonist isoproterenol. STD-101-D1 also inhibits the tumor necrosis factor α (TNFα) response induced by lipopolysaccharide (LPS) both in vitro and in vivo, and shows high brain penetration. Other than the therapeutic role, this newly identified, functionally selective, partial agonist of ADRB1 is an invaluable research tool to study mechanisms of G protein-coupled receptor signal transduction.


Subject(s)
Adrenergic beta-1 Receptor Agonists/therapeutic use , Brain/metabolism , GTP-Binding Proteins/metabolism , Neurocognitive Disorders/drug therapy , Receptors, Adrenergic, beta-1/metabolism , Adrenergic beta-1 Receptor Agonists/chemistry , Adrenergic beta-1 Receptor Agonists/pharmacokinetics , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Animals , CHO Cells , Cell Line, Tumor , Cells, Cultured , Cricetinae , Cricetulus , Crystallography, X-Ray , Drug Discovery , Humans , Magnetic Resonance Spectroscopy , Male , Mice, Inbred C57BL , Models, Chemical , Models, Molecular , Molecular Structure , Neurocognitive Disorders/metabolism , Permeability , Phenyl Ethers/chemistry , Phenyl Ethers/pharmacokinetics , Phenyl Ethers/therapeutic use , Propanolamines/chemistry , Propanolamines/pharmacokinetics , Propanolamines/therapeutic use , Protein Binding , Rats, Sprague-Dawley , Receptors, Adrenergic, beta-1/chemistry , Structure-Activity Relationship
14.
J Med Chem ; 60(16): 7029-7042, 2017 08 24.
Article in English | MEDLINE | ID: mdl-28682065

ABSTRACT

A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.


Subject(s)
NAV1.7 Voltage-Gated Sodium Channel/metabolism , Phenyl Ethers/pharmacology , Sulfonamides/pharmacology , Voltage-Gated Sodium Channel Blockers/pharmacology , Cell Line , Cytochrome P-450 CYP2C9/metabolism , Cytochrome P-450 CYP2C9 Inhibitors/chemical synthesis , Cytochrome P-450 CYP2C9 Inhibitors/chemistry , Cytochrome P-450 CYP2C9 Inhibitors/pharmacokinetics , Cytochrome P-450 CYP2C9 Inhibitors/pharmacology , Cytochrome P-450 CYP3A/metabolism , Cytochrome P-450 CYP3A Inhibitors/chemical synthesis , Cytochrome P-450 CYP3A Inhibitors/chemistry , Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Drug Design , Humans , Microsomes, Liver/metabolism , NAV1.7 Voltage-Gated Sodium Channel/chemistry , Phenyl Ethers/chemical synthesis , Phenyl Ethers/chemistry , Phenyl Ethers/pharmacokinetics , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/chemistry , Sulfonamides/pharmacokinetics , Voltage-Gated Sodium Channel Blockers/chemical synthesis , Voltage-Gated Sodium Channel Blockers/chemistry , Voltage-Gated Sodium Channel Blockers/pharmacokinetics
15.
Behav Brain Res ; 333: 54-66, 2017 08 30.
Article in English | MEDLINE | ID: mdl-28648684

ABSTRACT

Unlike majority of current antidepressants, HBK-15-a 5-HT1A and 5-HT7 receptor antagonist - showed memory-enhancing properties. In this study, we aimed to further characterize pharmacological profile of HBK-15 and investigate its antidepressant- and anxiolytic-like activity in the mouse model of unpredictable chronic mild stress. We used sucrose consumption test, forced swim test and elevated plus maze test as behavioral endpoints. We also evaluated the influence of HBK-15 on brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus and prefrontal cortex, as well as body weight, relative adrenal glands weight and plasma corticosterone level in the stressed mice. We utilized LC/MS/MS method to determine HBK-15 concentration in plasma and brain. We evaluated pharmacokinetic profile and distribution to brain of HBK-15 (2.5mg/kg) after intravenous (i.v.) and intraperitoneal (i.p.) administration in CD-1 mice. HBK-15 (2.5mg/kg but not 1.25mg/kg) and fluoxetine (10mg/kg) protected stressed mice from anhedonic-, depressive- and anxiety-like behaviors, decreases in the BDNF and NGF levels in the hippocampus and prefrontal cortex, increases in plasma corticosterone levels and relative adrenal glands weight. The pharmacokinetic analysis demonstrated a rapid absorption of HBK-15 after i.p. administration (tmax=5min), a short half-life (t0.5=74min), large volume of distribution (Vss=3.7L/kg) and bioavailability after i.p. administration equal 25%. HBK-15 administered i.v. and i.p. significantly penetrated brain. Our results suggest that the blockade of serotonergic 5-HT1A and 5-HT7 receptors might be beneficial in the treatment of depressive disorders with cognitive dysfunction.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Brain/metabolism , Corticosterone/blood , Mental Disorders/drug therapy , Nerve Growth Factor/metabolism , Phenyl Ethers/therapeutic use , Piperazines/therapeutic use , Serotonin Antagonists/therapeutic use , Adrenal Glands/drug effects , Adrenal Glands/pathology , Animals , Brain/drug effects , Cytokines/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Locomotion/drug effects , Male , Maze Learning/drug effects , Mental Disorders/etiology , Mice , Phenyl Ethers/pharmacokinetics , Phenyl Ethers/pharmacology , Piperazines/pharmacokinetics , Piperazines/pharmacology , Serotonin Antagonists/pharmacokinetics , Serotonin Antagonists/pharmacology , Stress, Psychological/complications , Sucrose/metabolism , Swimming/psychology
16.
Ann Nucl Med ; 31(4): 273-282, 2017 May.
Article in English | MEDLINE | ID: mdl-28181119

ABSTRACT

Objectives In PET studies for neuroreceptors, tracer kinetics are described by the two-tissue compartment model (2-TCM), and binding parameters, including the total distribution volume (V T), non-displaceable distribution volume (V ND), and binding potential (BPND), can be determined from model parameters estimated by kinetic analysis. The stability of binding parameter estimates depends on the kinetic characteristics of radioligands. To describe these kinetic characteristics, we previously developed a two-phase graphic plot analysis in which V ND and V T can be estimated from the x-intercept of regression lines for early and delayed phases, respectively. In this study, we applied this graphic plot analysis to visual evaluation of the kinetic characteristics of radioligands for neuroreceptors, and investigated a relationship between the shape of these graphic plots and the stability of binding parameters estimated by the kinetic analysis with 2-TCM in simulated brain tissue time-activity curves (TACs) with various binding parameters. Methods 90-min TACs were generated with the arterial input function and assumed kinetic parameters according to 2-TCM. Graphic plot analysis was applied to these simulated TACs, and the curvature of the plot for each TAC was evaluated visually. TACs with several noise levels were also generated with various kinetic parameters, and the bias and variation of binding parameters estimated by kinetic analysis were calculated in each TAC. These bias and variation were compared with the shape of graphic plots. Results The graphic plots showed larger curvature for TACs with higher specific binding and slower dissociation of specific binding. The quartile deviations of V ND and BPND determined by kinetic analysis were smaller for radioligands with slow dissociation. Conclusions The larger curvature of graphic plots for radioligands with slow dissociation might indicate a stable determination of V ND and BPND by kinetic analysis. For investigation of the kinetics of radioligands, such kinetic characteristics should be considered.


Subject(s)
Brain/diagnostic imaging , Brain/metabolism , Positron-Emission Tomography/methods , Radiopharmaceuticals/pharmacokinetics , Sensory Receptor Cells/metabolism , Acetamides/pharmacokinetics , Adult , Carbon Radioisotopes/pharmacokinetics , Computer Simulation , Humans , Kinetics , Least-Squares Analysis , Linear Models , Magnetic Resonance Imaging , Male , Models, Neurological , Naproxen/pharmacokinetics , Phenyl Ethers/pharmacokinetics
17.
Mol Imaging Biol ; 19(1): 153-161, 2017 02.
Article in English | MEDLINE | ID: mdl-27402093

ABSTRACT

PURPOSE: GSK2647544 is a potent and specific inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), which was in development as a potential treatment for Alzheimer's disease (AD). In order to refine therapeutic dose predictions and confirm brain penetration, a radiolabelled form of the inhibitor, [18F]GSK2647544, was manufactured for use in a positron emission tomography (PET) biodistribution study. PROCEDURES: [18F]GSK2647544 was produced using a novel, copper iodide (Cu(I)) mediated, [18F]trifluoromethylation methodology. Healthy male subjects (n = 4, age range 34-42) received an oral dose of unlabelled GSK2647544 (100 mg) and after 2 h an intravenous (iv) injection of [18F]GSK2647544 (average injected activity and mass were 106 ± 47 MBq and 179 ± 55 µg, respectively) followed by dynamic PET scans for 120 min. Defined regions of interest (ROI) throughout the brain were used to obtain regional time-activity curves (TACs) and compartmental modelling analysis used to estimate the primary outcome measure, whole brain volume of distribution (VT). Secondary PK and safety endpoints were also recorded. RESULTS: PET dynamic data were successfully obtained from all four subjects and there were no clinically significant variations of the safety endpoints. Inspection of the TACs indicated a relatively homogenous uptake of [18F]GSK2647544 across all the ROIs examined. The mean whole brain VT was 0.56 (95 % CI, 0.41-0.72). Secondary PK parameters, Cmax (geometric mean) and Tmax (median), were 354 ng/ml and 1.4 h, respectively. Metabolism of GSK2647544 was relatively consistent across subjects, with 20-40 % of the parent compound [18F]GSK2647544 present after 120 min. CONCLUSIONS: The study provides evidence that GSK2647544 is able to cross the blood brain barrier in healthy male subjects leading to a measurable brain exposure. The administered doses of GSK2647544 were well tolerated. Exploratory modelling suggested that a twice-daily dose of 102 mg, at steady state, would provide ~80 % trough inhibition of brain Lp-PLA2 activity. TRIAL REGISTRATION: Clintrials.gov: NCT01924858.


Subject(s)
1-Alkyl-2-acetylglycerophosphocholine Esterase/antagonists & inhibitors , Brain/metabolism , Fluorine Radioisotopes/chemistry , Phenyl Ethers/pharmacology , Phenyl Ethers/pharmacokinetics , Pyrimidinones/pharmacology , Pyrimidinones/pharmacokinetics , 1-Alkyl-2-acetylglycerophosphocholine Esterase/metabolism , Adult , Animals , Humans , Image Processing, Computer-Assisted , Male , Mice , Middle Aged , Phenyl Ethers/adverse effects , Phenyl Ethers/blood , Pyrimidinones/adverse effects , Pyrimidinones/blood , Rats , Time Factors , Tissue Distribution/drug effects
18.
J Infect Dis ; 215(3): 335-343, 2017 Feb 01.
Article in English | MEDLINE | ID: mdl-27932608

ABSTRACT

BACKGROUND: Immunodeficient individuals who excrete vaccine-derived polioviruses threaten polio eradication. Antivirals address this threat. METHODS: In a randomized, blinded, placebo-controlled study, adults were challenged with monovalent oral poliovirus type 1 vaccine (mOPV1) and subsequently treated with capsid inhibitor pocapavir or placebo. The time to virus negativity in stool was determined. RESULTS: A total of 144 participants were enrolled; 98% became infected upon OPV challenge. Pocapavir-treated subjects (n = 93) cleared virus a median duration of 10 days after challenge, compared with 13 days for placebo recipients (n = 48; P = .0019). Fifty-two of 93 pocapavir-treated subjects (56%) cleared virus in 2-18 days with no evidence of drug resistance, while 41 of 93 (44%) treated subjects experienced infection with resistant virus while in the isolation facility, 3 (3%) of whom were infected at baseline, before treatment initiation. Resistant virus was also observed in 5 placebo recipients (10%). Excluding those with resistant virus, the median time to virus negativity was 5.5 days in pocapavir recipients, compared with 13 days in placebo recipients (P < .0001). There were no serious adverse events and no withdrawals from the study. CONCLUSIONS: Treatment with pocapavir was safe and significantly accelerated virus clearance. Emergence of resistant virus and transmission of virus were seen in the context of a clinical isolation facility. CLINICAL TRIALS REGISTRATION: EudraCT 2011-004804-38.


Subject(s)
Antiviral Agents/therapeutic use , Phenyl Ethers/therapeutic use , Poliomyelitis/prevention & control , Poliovirus Vaccine, Oral/administration & dosage , Adult , Cohort Studies , Female , Humans , Male , Middle Aged , Phenyl Ethers/pharmacokinetics , Single-Blind Method , Treatment Outcome , Viral Load/drug effects , Virus Shedding , Virus Uncoating/drug effects
19.
Int J Clin Pharmacol Ther ; 54(12): 935-949, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27719741

ABSTRACT

OBJECTIVE: To evaluate in healthy volunteers the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) potential of GSK2647544, (a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor). METHODS: Study 1 was a single-blind, randomized, placebo-controlled, crossover study with healthy male volunteers randomized to receive single escalating oral doses (0.5 - 750 mg) of GSK2647544. Study 2 was a single-blind, randomized, placebo-controlled study with healthy volunteers randomized to receive repeat doses (80 mg) of GSK2647544. The drug-drug interaction of GSK2647544 with simvastatin was also evaluated in study 2. RESULTS: Across both studies GSK2647544 doses were generally well tolerated with no GSK2647544-related clinically significant findings. GSK2647544 was readily absorbed and its plasma concentration declined bi-exponentially with a terminal half-life ranging from 8 to 16 hours. Plasma exposure of GSK2647544 increased approximately dose-proportionally. There was GSK2647544 dose-dependent inhibition of plasma Lp-PLA2 activity, with a trough inhibition (12 hours after dose) of 85.6% after 7-day twice daily dosing. The administration of simvastatin concomitantly with GSK2647544 increased the overall exposure (area under the plasma concentration-time curve and maximum plasma concentration) of simvastatin and simvastatin acid by 3.6- to 4.3-fold and 1.5- to 3.1-fold, respectively. CONCLUSIONS: GSK2647544 was generally well tolerated and had a reasonable PK-PD profile. The clinically significant drug-drug interaction led to an early termination of study 2.
.


Subject(s)
1-Alkyl-2-acetylglycerophosphocholine Esterase/antagonists & inhibitors , Phenyl Ethers/adverse effects , Pyrimidinones/adverse effects , Adult , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Female , Healthy Volunteers , Humans , Male , Phenyl Ethers/pharmacokinetics , Phenyl Ethers/pharmacology , Pyrimidinones/pharmacokinetics , Pyrimidinones/pharmacology , Simvastatin/pharmacology , Single-Blind Method
20.
ACS Chem Neurosci ; 7(11): 1482-1487, 2016 11 16.
Article in English | MEDLINE | ID: mdl-27551907

ABSTRACT

Matrix metalloproteinase (MMP)-2 knockout (KO) mice show impaired neurological recovery after spinal cord injury (SCI), suggesting that this proteinase is critical to recovery processes. However, this finding in the KO has been confounded by a compensatory increase in MMP-9. We synthesized the thiirane mechanism-based inhibitor ND-378 and document that it is a potent (nanomolar) and selective slow-binding inhibitor of MMP-2 that does not inhibit the closely related MMP-9 and MMP-14. ND-378 crosses the blood-spinal cord barrier, achieving therapeutic concentrations in the injured spinal cord. Spinal-cord injured mice treated with ND-378 showed no change in long-term neurological outcomes, suggesting that MMP-2 is not a key determinant of locomotor recovery.


Subject(s)
Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology , Phenyl Ethers/pharmacology , Recovery of Function/physiology , Spinal Cord Injuries/enzymology , Spinal Cord/enzymology , Sulfones/pharmacology , Animals , Disease Models, Animal , Drug Design , Drug Evaluation, Preclinical , Male , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase Inhibitors/chemical synthesis , Matrix Metalloproteinase Inhibitors/pharmacokinetics , Mice , Mice, Knockout , Molecular Docking Simulation , Molecular Structure , Motor Activity/drug effects , Motor Activity/physiology , Phenyl Ethers/chemical synthesis , Phenyl Ethers/pharmacokinetics , Recovery of Function/drug effects , Spinal Cord/drug effects , Spinal Cord Injuries/drug therapy , Sulfones/chemical synthesis , Sulfones/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...